Read more about Regulatory nod given to conduct clinical trials of Colchicine: CSIR on Business Standard. The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct clinical trial of Colchicine on COVID-19 patients, according to a statement on Saturday.Ram Vishwakarma, the advisor to
The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct a clinical trial of Colchicine on COVID-19 patients.
Ram Vishwakarma, the advisor to the CSIR Director-General, said Colchicine, in combination with standard care, will be an important therapeutic intervention for COVID-19 patients with cardiac co-morbidities
Share
New Delhi: CSIR’s new entity, the CSIR-National Institute of Science communication and Policy Research (NIScPR)), New Delhi, organized a half-day online session on COVID-19 in children yesterday (04 June 2021). The session was focused on the recent second wave outbreak and the impact of COVID-19 on children, threats and necessary protocols required for the safety of children. The Chief Guest of the webinar was Dr. V. Vijayalakshmi; Additional Commissioner (Academics), KVS (HQ), New Delhi and the Guest speaker was Prof. Dr. R. Somasekar, Professor of Pediatrics, Sree Balaji Medical College & Hosptial (SBMCH), Chennai, Tamil Nadu and Executive Board Member 2021, Indian Academy of Paediatrics (IAP). The program was attended by about 150 delegates including several dignitaries, faculty members, researchers and scientists, and students from various schools through the link made available on Face Book by CSIR-NIScPR.